Observational Study of Incidence of Breakthrough Cancer Pain and How it is Treated (Break-1)
Multicenter Observational Study of the Incidence and Treatment Modalities of Breakthrough Cancer Pain in Patients With Chronic Cancer Pain
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Castellammare di Stabia, Italy
- Ospedale San Leonardo
-
Napoli, Italy
- Istituto Nazionale dei Tumori , Unita Terapia Antalgica
-
Nola, Italy
- S. Maria della Pietà
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of neoplasm in advanced stage
- Chronic pain controlled for at least one week with opioids 60 mg / day morphine equivalent
- 1-6 episodes of BTcP within any of 3 days previous to registration into study
- Signed Informed Consent
Exclusion Criteria:
· More than 6 episodes of BTcP within any of 3 days previous to registration into study
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Advanced cancer patients with pain
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
number of patients who experience BTcP
Time Frame: one year
|
one year
|
|
treatments used to treat BTcP
Time Frame: one year
|
one year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
pain intensity
Time Frame: 4 weeks
|
evaluate the relationship between pain intensity, patient characteristics, and clinician choice of pain medication
|
4 weeks
|
|
time to pain relief of BTcP
Time Frame: 4 weeks
|
4 weeks
|
|
|
initial dose of therapy (in morphine equivalents) for BTcP
Time Frame: 4 weeks
|
to verify a correlation between initial dose for BTcP and daily dose of baseline pain therapy
|
4 weeks
|
|
effective dose for BTcP
Time Frame: 4 weeks
|
to verify a correlation between effective dose for BTcP and daily dose of baseline pain therapy (dose reported in morphine equivalents)
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Arturo Cuomo, M.D., NCI Naples, Division of Pain Therapy
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Break-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.